CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 115 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.06 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $17,573 | -13.1% | 10,217 | -23.7% | 0.00% | – |
| Q1 2023 | $20,229 | -87.8% | 13,397 | -87.1% | 0.00% | – |
| Q4 2022 | $166,279 | -14.3% | 103,924 | -22.3% | 0.00% | – |
| Q3 2022 | $194,000 | -43.4% | 133,693 | -28.7% | 0.00% | – |
| Q2 2022 | $343,000 | -83.1% | 187,542 | -75.3% | 0.00% | – |
| Q1 2022 | $2,026,000 | -26.5% | 758,589 | +19.1% | 0.00% | -100.0% |
| Q4 2021 | $2,758,000 | -51.1% | 636,946 | -42.6% | 0.00% | 0.0% |
| Q3 2021 | $5,645,000 | -6.3% | 1,109,065 | +16.5% | 0.00% | 0.0% |
| Q2 2021 | $6,026,000 | +272.9% | 952,017 | +355.3% | 0.00% | – |
| Q1 2021 | $1,616,000 | +8.5% | 209,102 | -8.1% | 0.00% | – |
| Q4 2020 | $1,490,000 | -19.9% | 227,449 | -18.7% | 0.00% | -100.0% |
| Q3 2020 | $1,861,000 | -19.6% | 279,823 | +0.7% | 0.00% | 0.0% |
| Q2 2020 | $2,315,000 | +118.6% | 277,845 | +101.3% | 0.00% | – |
| Q1 2020 | $1,059,000 | -68.2% | 138,048 | -65.5% | 0.00% | -100.0% |
| Q4 2019 | $3,328,000 | +16.0% | 400,455 | +3.0% | 0.00% | 0.0% |
| Q3 2019 | $2,869,000 | -37.1% | 388,730 | -4.3% | 0.00% | 0.0% |
| Q2 2019 | $4,559,000 | +114.8% | 406,357 | +105.9% | 0.00% | 0.0% |
| Q1 2019 | $2,122,000 | -71.8% | 197,375 | -60.4% | 0.00% | -50.0% |
| Q4 2018 | $7,521,000 | -10.9% | 498,092 | +9.2% | 0.00% | 0.0% |
| Q3 2018 | $8,437,000 | -29.2% | 456,053 | -12.5% | 0.00% | -33.3% |
| Q2 2018 | $11,913,000 | -0.0% | 521,108 | +24.4% | 0.00% | 0.0% |
| Q1 2018 | $11,917,000 | +23.4% | 418,892 | -8.5% | 0.00% | +50.0% |
| Q4 2017 | $9,660,000 | +63.5% | 457,619 | +40.7% | 0.00% | +100.0% |
| Q3 2017 | $5,909,000 | +198.4% | 325,165 | +154.5% | 0.00% | 0.0% |
| Q2 2017 | $1,980,000 | +942.1% | 127,776 | +1063.5% | 0.00% | – |
| Q1 2017 | $190,000 | -40.4% | 10,982 | -28.1% | 0.00% | – |
| Q4 2015 | $319,000 | – | 15,278 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |